Allergan to cash in on eyelash stimulant effect of glaucoma drug

June 13, 2008

Following positive clinical trial results, Allergan, the makers of bimatoprost, are submitting a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking a new indication for the prostaglandin analogue as an eyelash growth stimulant.

Related Content:

Articles | Glaucoma